New cancer drug cost-effectiveness assessment algorithm proposed by experts
…minor amendment to the Reimbursement Act, experts at Fundacja Alivia said. A report published by Alivia earlier this year claimed more than half of new cancer drugs that have been approved in Europe over the past 12 years – 50 out of 94 – are not reimbursed in Poland.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)